Publisher: First Affiliated Hospital of Jinan University

Date: March 1st, 2024

The research team at Jinan University, in collaboration with the First Affiliated Hospital and the School of Basic Medicine and Public Health, has achieved a significant milestone in the field of medical research. On February 26th, Dr. Liu Siyang, a postdoctoral researcher from Li Yangqiu's team at the First Affiliated Hospital of Jinan University, partnered with Professor Wu Yilong's team from Guangdong Provincial People's Hospital to publish a clinical trial results article titled PD-L1 expression guidance on sinilimab versus pembrolizumab with or without platinum doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): a phase 2, randomized, controlled trial in the prestigious domestic journal, Science Bulletin.

This groundbreaking study marks the first prospective research endeavor directly comparing two PD-1 inhibitors, shedding light on the efficacy and safety of domestically produced and imported PD-1 inhibitors. The findings indicate that China's independently innovative immunotherapy drugs are not only on par with international drugs in terms of efficacy and safety but also exhibit superior cost-effectiveness, positioning them as a promising treatment option for advanced non-small cell lung cancer.

The research article, co-authored by Professor Wu Yilong, Professor Zhou Qing from Guangdong Provincial People's Hospital, and Researcher Li Yangqiu from the First Affiliated Hospital/School of Basic Medicine and Public Health of Jinan University, features Dr. Liu Siyang from the First Affiliated Hospital of Jinan University, Dr. Huang Jie, and Dr. Deng Jiayi from Guangdong Provincial People's Hospital as co-first authors. The research work has garnered support from the Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine, backed by the Guangdong Provincial Medical Leading Talent Research Fund, the National Natural Science Foundation of China, the China Postdoctoral Science Foundation, and the high-level hospital construction projects of Guangdong Provincial People's Hospital.

This significant achievement underscores the commitment and excellence of the research teams at Jinan University and their collaborators in advancing medical knowledge and contributing to the development of innovative and cost-effective treatment options for cancer patients. The published paper can be accessed through the following link: [Science Bulletin Article] 

(https://www.sciengine.com/SB/doi/10.1016/j.scib.2023.12.046)